b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">32189549</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>17</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1750-7448</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>12</Volume>\n                    <Issue>4</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>03</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Immunotherapy</Title>\n                <ISOAbbreviation>Immunotherapy</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>235-243</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.2217/imt-2019-0131</ELocationID>\n            <Abstract>\n                <AbstractText><b>Aim:</b> The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP)\xc2\xa0in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. <b>Materials &amp; methods:</b> We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. <b>Results:</b> Of 207 patients included in this analysis, 22% patients received TBP. A total of\xc2\xa036% achieved a clinical benefit. A total of\xc2\xa027% patients had a progression-free interval over 6\xc2\xa0months after receiving TBP. <b>Conclusion:</b> A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Reinhorn</LastName>\n                    <ForeName>Daniel</ForeName>\n                    <Initials>D</Initials>\n                    <Identifier Source="ORCID">0000-0002-7717-9032</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jacobi</LastName>\n                    <ForeName>Oded</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Icht</LastName>\n                    <ForeName>Oded</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dudnik</LastName>\n                    <ForeName>Elizabeth</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rotem</LastName>\n                    <ForeName>Ofer</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zer</LastName>\n                    <ForeName>Alona</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Goldstein</LastName>\n                    <ForeName>Daniel A</ForeName>\n                    <Initials>DA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Health Policy &amp; Management, Gillings School of Global Public Health, University of North Carolina, NC 27599-7400, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>19</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Immunotherapy</MedlineTA>\n            <NlmUniqueID>101485158</NlmUniqueID>\n            <ISSNLinking>1750-743X</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">immune checkpoint inhibitors</Keyword>\n            <Keyword MajorTopicYN="Y">metastatic</Keyword>\n            <Keyword MajorTopicYN="Y">nivolumab</Keyword>\n            <Keyword MajorTopicYN="Y">non-small-cell lung cancer</Keyword>\n            <Keyword MajorTopicYN="Y">pembrolizumab</Keyword>\n            <Keyword MajorTopicYN="Y">treatment beyond progression</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32189549</ArticleId>\n            <ArticleId IdType="doi">10.2217/imt-2019-0131</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'